Research & Markets Announces the Release of 'Breast Cancer Therapies Markets'

Share Article

Provides comprehensive information on major and minor shapers of the breast cancer drug treatment landscape.

News Image
Breast cancer therapies are entering a new era as game-changers emerge

Breast cancer therapies are entering a new era as game-changers emerge for each of the major breast cancer patient populations. New market entrants must possess drug profiles and a savvy clinical development program to overcome such barriers to entry as a stringent regulatory environment and the incursion of cost containment within oncology.

This TriMark Publications report provides comprehensive information on major and minor shapers of the breast cancer drug treatment landscape. The study includes detailed discussions on the impact of critical factors, such as genericization, patent cliffs, drug shortages, reimbursement, predictive testing and personalized medicine, to help current and contemplative drug sponsors navigate the breast cancer pharmacotherapeutic market.

Moreover, this report contains a detailed analysis of each of the seven main modalities of breast cancer therapies, i.e., hormone therapy, surgery, radiation, molecular targeted therapy, chemotherapy, hormone treatment and targeted drug therapy. Additionally, this study examines prescribing trends and the arrival of the first biosimilar agents and electronic records in post-marketing surveillance.

For more information please visit http://www.researchandmarkets.com/research/jc48q6/breast_cancer

Research and Markets
Laura Wood, Senior Manager,
press(at)researchandmarkets(dot)com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laura Wood
Follow us on
Visit website